Roth Mkm Reaffirms "Buy" Rating for Insmed (NASDAQ:INSM)

Key Points

• Roth Mkm reaffirmed a Buy rating on Insmed with a $212 price target — implying roughly a 47% upside — and the consensus analyst target sits near $213.23 with most firms rated Buy.
• Insmed shares traded around $143.88 (52‑week range $63.81–$212.75) and the company reported quarterly EPS of -$1.54 (missing estimates) despite revenue rising ~152.6% year‑over‑year.
• Insiders have been net sellers recently (179,777 shares worth about $28.4M in the last three months), even as large institutions like Vanguard, Darwin and State Street hold sizeable stakes.

Insmed (NASDAQ:INSM - Get Free Report)'s stock had its "buy" rating reissued by Roth Mkm in a research note issued on Friday,Benzinga reports. They presently have a $212.00 price target on the biopharmaceutical company's stock. Roth Mkm's price objective suggests a potential upside of 47.35% from the company's current price.

Several other equities research analysts have also recently weighed in on the stock. Jefferies Financial Group started coverage on shares of Insmed in a research report on Monday, March 16th. They set a "buy" rating and a $228.00 price target for the company. Bank of America increased their price target on shares of Insmed from $211.00 to $213.00 and gave the company a "buy" rating in a research report on Tuesday, March 24th. Citigroup reissued an "outperform" rating on shares of Insmed in a research report on Thursday, December 18th. HC Wainwright increased their price target on shares of Insmed from $230.00 to $245.00 and gave the company a "buy" rating in a research report on Thursday, March 26th. Finally, Wells Fargo & Company dropped their price target on shares of Insmed from $208.00 to $175.00 and set an "overweight" rating for the company in a research report on Monday, March 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $213.23.

Insmed Trading Up 0.8%

Shares of Insmed stock traded up $1.09 during trading on Friday, reaching $143.88. The company's stock had a trading volume of 1,072,886 shares, compared to its average volume of 2,461,763. Insmed has a 52-week low of $63.81 and a 52-week high of $212.75. The company has a market cap of $31.06 billion, a price-to-earnings ratio of -22.41 and a beta of 1.10. The firm's 50-day moving average is $150.06 and its two-hundred day moving average is $167.29. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). The business had revenue of $263.84 million during the quarter, compared to analysts' expectations of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. Insmed's revenue for the quarter was up 152.6% on a year-over-year basis. During the same period last year, the company posted ($1.32) EPS. On average, sell-side analysts anticipate that Insmed will post -4.56 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $150.98, for a total value of $2,964,945.24. Following the completion of the transaction, the insider directly owned 51,871 shares in the company, valued at $7,831,483.58. This trade represents a 27.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 13,396 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $147.79, for a total transaction of $1,979,794.84. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company's stock, valued at approximately $44,512,131.15. The trade was a 4.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 179,777 shares of company stock worth $28,412,777 in the last three months. 2.10% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

Several institutional investors have recently bought and sold shares of INSM. Vanguard Group Inc. raised its position in shares of Insmed by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company's stock valued at $3,668,127,000 after purchasing an additional 1,140,524 shares during the period. Darwin Global Management Ltd. grew its position in shares of Insmed by 2.3% during the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company's stock worth $3,644,274,000 after purchasing an additional 475,832 shares in the last quarter. Capital International Investors grew its position in shares of Insmed by 1.0% during the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company's stock worth $1,087,830,000 after purchasing an additional 74,994 shares in the last quarter. State Street Corp raised its stake in Insmed by 30.6% during the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company's stock valued at $905,312,000 after purchasing an additional 1,217,390 shares during the period. Finally, Artisan Partners Limited Partnership raised its stake in Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company's stock valued at $711,076,000 after purchasing an additional 1,623,342 shares during the period.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.